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http://dx.doi.org/10.1016/j.ccell.2014.10.009SUMMARYHomeotic (HOX) genes are dysregulated in multiple malignancies, including several AML subtypes.
We demonstrate that H3K79 dimethylation (H3K79me2) is converted to monomethylation (H3K79me1)
at HOX loci as hematopoietic cells mature, thus coinciding with a decrease in HOX gene expression.
We show that H3K79 methyltransferase activity as well as H3K79me1-to-H3K79me2 conversion is regulated
by the DOT1L cofactor AF10. AF10 inactivation reverses leukemia-associated epigenetic profiles, precludes
abnormal HOXA gene expression, and impairs the transforming ability of MLL-AF9, MLL-AF6, and NUP98-
NSD1 fusions—mechanistically distinct HOX-activating oncogenes. Furthermore, NUP98-NSD1-trans-
formed cells are sensitive to small-molecule inhibition of DOT1L. Our findings demonstrate that pharmaco-
logical inhibition of the DOT1L/AF10 complex may provide therapeutic benefits in an array of malignancies
with abnormal HOXA gene expression.INTRODUCTION
The clustered homeobox (HOX) genes are conserved throughout
evolution and play important roles in development (Lappin et al.,
2006). Multiple human malignancies, including approximately
50% of acute myeloid leukemia (AML) cases, show dysregulated
expression of the clustered homeobox genes (Argiropoulos and
Humphries, 2007). Specific members of the HOX cluster are
critical for hematopoietic stem cell (HSC) self-renewal, and the
expression of a particular subset of the HOXA gene cluster, spe-
cifically the Hoxa7–10 genes, is sharply downregulated when
murine HSCs differentiate to granulocyte macrophage progeni-
tors (GMPs) (Krivtsov et al., 2006). HOXA gene repression inSignificance
A broad array of human malignancies shows aberrant express
of the HOXA gene cluster. Our study demonstrates that the DO
and H3K79me1-to-H3K79me2 conversion by DOT1L. AF10 inac
nome, suppressing the ability of multipleHOX-activating oncog
evidence that transformation driven byMLL fusions aswell as t
is critically dependent on the ability of AF10 to stimulate DOT1L
tions because they provide a strong rationale for therapeutica
refractory leukemias.
896 Cancer Cell 26, 896–908, December 8, 2014 ª2014 Elsevier Inc.myeloid progenitors such as GMPs is critical because aberrant
HOXA gene expression is a central component of a leukemo-
genic gene expression program driven by diverse oncogenes
(Argiropoulos and Humphries, 2007).
One of the classic examples of a malignancy with aberrant
HOXA activation is leukemia with rearrangements of the mixed
lineage leukemia gene (MLL), an aggressive disease with limited
treatment options and poor survival rates. In these leukemias,
MLL is fused to one of more than 60 different fusion partners,
leading to the formation of dominantly acting oncogenic fusion
proteins (Krivtsov and Armstrong, 2007). Expression of the
MLL-fusion oncoprotein perpetuates inappropriate high-level
HOXA gene expression in GMPs and induces leukemias inion of the clustered homeobox genes, particularly the genes
T1L-interacting protein AF10 regulates the HMTase activity
tivation causes widespread changes to the leukemia epige-
enes to induce leukemic transformation. Our results provide
he recurrent AML-associated NUP98-NSD1 fusion oncogene
activity. These findings have profound therapeutic implica-
lly targeting the DOT1L-AF10 complex in multiple types of
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sov et al., 2006; Somervaille and Cleary, 2006). Some of the
recurrent C-terminal fusion partners of MLL, such as AF9, ENL,
AF17, and AF10, normally interact with the histone methyltrans-
ferase DOT1L (reviewed in Deshpande et al., 2012). DOT1L is
the sole histonemethyltransferase that catalyzes histone 3 lysine
79 monomethylation (H3K79me1), dimethylation (H3K79me2),
and trimethylation (H3K79me3) (reviewed in Nguyen and Zhang,
2011), chromatin modifications that are widely associated with
highly expressed genes in mammalian cells (Steger et al.,
2008). MLL fusions with DOT1L-interacting proteins are believed
to misdirect DOT1L to the promoters of HOXA genes, leading
to H3K79 methylation and constitutive activation of these genes
in MLL-rearranged leukemia. However, recent studies have re-
ported that MLL fusions with no apparent DOT1L recruiting
activity are also dependent on the H3K79-methylating activity
of DOT1L for transformation (Chang et al., 2010; Deshpande
et al., 2013). These studies offer an alternative, although not
mutually exclusive, possibility: H3K79 methylation may be
broadly important for the epigenetic regulation of specific
HOXA genes and HOXA gene-mediated oncogenesis. The
most interesting implication of this alternative hypothesis is
that the transforming activity of otherHOX-activating oncogenes
may also depend on H3K79 methylation.
There is tremendous interest in DOT1L as a potential thera-
peutic target in MLL-rearranged leukemia, and clinical trials
with a DOT1L small-molecule inhibitor are currently ongoing.
However, little is known about potential cofactors that mediate
the chromatin-modifying activity of DOT1L. DOT1L has been
identified as a component of large multiprotein complexes that
are associated with transcribed genes (Mohan et al., 2010;
Mueller et al., 2009), although critical constituents of the
DOT1L complex are not well defined. DOT1L binds to the plant
homeodomain (PHD) and leucine zipper-containing protein
AF10, an interaction that is highly conserved throughout evolu-
tion. Despite the fact that AF10 is involved in recurrent chromo-
somal translocations that fuse it to one of at least five different
fusion partners apart fromMLL in human leukemia (Brandimarte
et al., 2013; Dreyling et al., 1996; Soler et al., 2013; Zhang et al.,
2012), there have been few studies aimed at understanding the
functional and physiological role of AF10 in mammalian cells
(Chamorro-Garcia et al., 2012; Linder et al., 2000). AF10-rear-
ranged (AF10-R) leukemias show two recurrent features: con-
sistent retention of the leucine-rich DOT1L-interacting AF10
domain in the fusion and the aberrant upregulation of HOXA
cluster genes. Strikingly, these two features span all AF10-R
leukemias regardless of the N-terminal fusion partner. These ob-
servations, taken together with the fact that DOT1L as well as
AF10 orthologs regulate the expression of the bithorax gene
cluster in Drosophila (Perrin et al., 2003; Shanower et al.,
2005), strongly suggest that DOT1L and AF10 may be generally
involved in HOXA gene regulation.
RESULTS
Normal and Malignant HOXA Gene Expression
Correlates with Higher H3K79 Methylation States
We wanted to test a potential role for DOT1L in the regulation
of HOXA gene expression in murine hematopoietic stem andCaprogenitor cells. We sorted lineageSca-1+c-Kit+ (LSK) cells,
which are enriched for HSCs, from bone marrow (BM) pre-
pared from Dot1lfl/fl mice crossed with interferon-inducible
Mx1-Cre transgenic mice in which Dot1l deletion was induced
upon administration of polyinosinic-polycytidylic acid (pIpC)
and compared these LSKs with their pIpC-injected Dot1l
wild-type counterparts. Gene expression analysis showed
that Hoxa9 and Meis1 were significantly downregulated in
LSKs with homozygous Dot1l deletion (Figure 1A), demon-
strating a role for DOT1L in the normal regulation of these ho-
meobox genes.
Because the state of H3K79 methylation could have
different functions, we assessed H3K79me1, H3K79me2, and
H3K79me3 in LSKs, which express high levels of Hoxa7–10 and
Meis1 genes, and compared them with GMPs, which express
much reduced levels of these genes (Krivtsov et al., 2006). We
performed chromatin immunoprecipitation sequencing (ChIP-
seq) using well characterized antibodies that predominantly
recognize H3K79me1, H3K79me2, or H3K79me3 (Figure S1A
available online). Each of the three H3K79 methylation states
directly correlated with gene expression levels and showed
broadly overlapping patterns across the genome (Figure S1B).
H3K79me3 demonstrated a more contracted pattern surround-
ing the transcription start sites (TSSs) (Figure S1B). Interestingly,
this analysis showed that the sharp decrease in Hoxa7–10
expression in GMPs compared with LSKs was accompanied by
a diminution in H3K79me2 and H3K79me3 at the HOXA genes,
with minimal changes in H3K79me1 (Figure 1B). In fact, some
genes, such as Hoxa9, showed higher H3K79me1 in GMPs
than in LSKs. Furthermore, the LSK-GMP transition was associ-
ated with an encroachment of histone H3 lysine 27 trimethylation
(H3K27me3) into the Hoxa7–10 gene cluster (Figure 1B), consis-
tent with the observed downregulation of these transcripts.
These results demonstrate that HOXA gene expression is corre-
latedwith higher H3K79methylation states during hematopoietic
differentiation and suggests that H3K79me1 may not be suffi-
cient to maintain high-level HOXA gene expression.
MLL-rearranged leukemias show constitutive expression of
the Hoxa7–10 gene cluster and Meis1, a process that is
dependent on H3K79 methylation. We therefore assessed
H3K79 methylation states in LSK-derived MLL-AF9 leukemias
by ChIP-seq. Similar to LSKs and GMPs, all three states
of H3K79 methylation showed overlapping profiles, with
H3K79me3 particularly enriched at genes where the MLL-AF9
fusion protein binds (Bernt et al., 2011) (Figure S1C and Table
S1). Strikingly, in contrast to the genome-wide profiles of
H3K79 methylation, promoters of HOXA genes were character-
ized by low levels of H3K79me1 and high levels of H3K79me2/
3 (Figure 1C; Figure S1D). The increased conversion of H3K79
methylation to higher methylation states at the Hoxa7–10
genes was accompanied by the absence of the repressive
H3K27me3 mark, as expected from the high-level expression
of these genes in MLL-AF9 leukemia cells (Figure 1C). We
then conducted a meta-analysis of H3K79me1/2/3 relation-
ships across MLL-AF9 target genes. Strikingly, MLL-AF9 target
genes showed low-level H3K79me1 and high-level H3K79me2/
3 profiles, observed on the Hoxa7–-10 and Meis1 genomic
loci (Figure 1D). Meta-analysis of the averaged H3K79me1
and H3K79me2 profiles across the body of MLL-AF9 targetncer Cell 26, 896–908, December 8, 2014 ª2014 Elsevier Inc. 897
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Figure 1. Histone Methylation Profiles in Normal Cells and MLL-AF9 Leukemia Cells
(A) Expression of Hoxa9 andMeis1 in LSKs sorted from Dot1lfl/fl or Dot1lWT/WT mice crossed with Mx1-Cre mice treated with pIpC 10 days before. The box plot
shows normalized expression values from six independent replicates. Whiskers represent the upper and lower limits of the range. Boxes represent the first and
third quartiles, and the line represents the median. *p < 0.05.
(B) Representative profiles for ChIP-seq using anti-H3K79me1, H3K79me2, H3K79me3, and H3K27me3 antibodies in LSK and GMP cells at the HOXA cluster.
The y axis scales represents read density per million sequenced reads, and the Hoxa5–10 genomic region is marked by a dotted red rectangle.
(C) Representative profiles for ChIP-seq using anti-H3K79me1, H3K79me2, H3K79me3, and H3K27me3 antibodies at various genomic loci in MLL-AF9 leukemia
cells. Binding of theMLL-AF9 fusion gene is shown at the bottom in green. The y axis scale represent read density permillion sequenced reads, and theHoxa5–10
genomic region is marked by a dotted red rectangle.
(D) Meta-analysis of the averaged ChIP-seq signal at four sets of genes across a +10 kb to 10 kb genomic region around the transcriptional start site.
See also Figure S1 and Table S1.
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Figure 2. The Impact of Genomic Af10 Dele-
tion on H3K79 Methylation
(A) Growth of the human leukemia cell lines
MOLM13 (MLL-AF9), THP1 (MLL-AF9), SEMK2
(MLL-AF4), HL60 (non-MLL-rearranged), and Ka-
sumi1 (non-MLL-rearranged) after transduction
with anti-AF10 and anti-AF17 shRNAs. Viable cells
were counted every 3–4 days, and cell numbers
after transduction with an anti-luciferase shRNA
(sh-Luc) were set as 100%.
(B) Western blots showing H3K79 methylation in
HOXA9-MEIS1-transformed clones with the indi-
cated floxed allele following empty vector (MIT) or
Cre expression.
(C) Quantification of integrated signals for area
under the curve values of the indicated clones.
Error bars represent SD.
See also Figure S2 and Table S2.
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nounced near the promoter-proximal regions of MLL-AF9
target genes (Figure S1D). In contrast, control sets of non-
MLL-AF9 target genes showed similar profiles of H3K79me1
and H3K79me2 across the gene body (Figure S1D). These
results demonstrate that, similar to normal hematopoietic dif-
ferentiation, higher degrees of H3K79me2/3, rather than
H3K79me1, correlate with high HOXA gene expression as
well as exclusion of the repressive H3K27me3 from the
Hoxa7–10 locus. This suggests that the expression of HOXA,
and perhaps other genes, is critically dependent on the con-
version of H3K79me1 to H3K79me2.
AF10 Is Critical for Higher H3K79-Methylated States
Given that H3K79me2, but not H3K79me1, correlated with
high-level expression of select genes, we wanted to determine
how the conversion of H3K79me1 to H3K79me2 is regulated.
We found that the expression of Dot1l transcripts does
not correlate with Hoxa5–10 gene expression in LSK com-
pared with GMP cells (Figure S2A), suggesting that Dot1l
transcript levels do not explain the HOXA locus-associated
decrease in H3K79me2 and H3K79me3 in GMPs. There is
increasing appreciation of the role of cofactor proteins in the
modulation of specific methylation states by chromatin-modi-
fying enzymes (Dou et al., 2006; Pasini et al., 2004). We there-
fore wondered whether a cofactor of DOT1L could be respon-
sible for enhancing the ability of DOT1L to catalyze increased
H3K79 di- or trimethylation at the HOXA genes. Even though
several DOT1L-interacting proteins have been reported (Mo-
han et al., 2010; Park et al., 2010), the composition of the
DOT1L complex in human leukemia cells remains undefined.
We purified the DOT1L complex from a human MLL-rear-Cancer Cell 26, 896–908,ranged and a MLL-germline cell line us-
ing protocols described previously (Kim
et al., 2009) and identified a number
of DOT1L-interacting proteins, notably
AF10, AF17, ILF2, MEF2C, HDAC1, and
CDK9 (Figure S2B and Table S2). Of
note, other than AF10 and AF17, most
other proteins were either found in lowabundance or were occasionally also retrieved from control
cells (Table S2). We focused our attention on the PHD and
octapeptide motif leucine zipper containing the paralogous
proteins AF10 and AF17 for further studies. To assess a poten-
tial role for AF10 or AF17 in the conversion from H3K79me1
to H3K79me2, we performed short hairpin RNA (shRNA)
knockdown experiments in human leukemia cell lines. We
found that AF10 suppression produced a clear reduction in
H3K79me2, but AF17 suppression had no observable effect
on H3K79 dimethylation (Figure S2C). In contrast to DOT1L
suppression, we observed that AF10 suppression led to the
reduction of H3K79me2 but not H3K79me1 (Figures S2C and
S2D). Next we performed proliferation assays with shRNAs
targeting AF10 or AF17 in human MLL-rearranged or MLL
germline leukemia cell lines. We found that AF10 knockdown
significantly impaired the proliferation of the MLL-rearranged
cell lines MOLM13, SEMK2, and THP1 but not the MLL germ-
line leukemia cell lines HL60 and Kasumi1 (Figure 2A; Fig-
ure S2E). In contrast, none of the cell lines were sensitive to
AF17 knockdown, suggesting that AF10 plays a more promi-
nent role in H3K79 methylation in MLL-rearranged leukemia
(Figure 2A). Moreover, the levels of Af10 but not Af17 corre-
lated with the decrease in HOXA gene expression in murine
LSK compared with GMP cells (Figure S2A), marking AF10
as a prime candidate for further studies.
Given the results above, we interrogated AF10 in more detail.
We generated a conditional Af10 knockout mouse (Figure S2F).
We first assessed the effect of AF10 loss on cells insensitive to
the loss of H3K79 methylation to avoid the confounding effects
of apoptosis or differentiation that might be seen in DOT1L-
dependent cells. For this, we used bone marrow cells trans-
formed with HOXA9 and MEIS1 or immortalized fibroblast cellDecember 8, 2014 ª2014 Elsevier Inc. 899
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Figure 3. The DOT1L-AF10 Interaction Is
Critical for MLL Transformation
(A) Schematic representation of colony assays.
(B) Pictures of representative colonies from cells
transformed with different oncogenes 7 days after
Af10 excision (Cre) compared with Af10-floxed
colonies (MIT).
(C) Wright-Giemsa-stained cytospins of MLL-AF9-
transformed cells 7 days after expression of the Cre
recombinase (Cre) or the control vector (MIT).
(D and E) Colony numbers obtained 7 days after
expression of the Cre recombinase in wild-type or
Af10-floxed MLL-AF9- (D) or MLL-AF6-trans-
formed (E) cells. *p = 0.013, **p = 0.04. Data
represent mean ± SEM values from three inde-
pendent experiments. p values were calculated
between the mean numbers of blast colonies in
Cre-expressing wild-type cells compared with Cre-
expressing Af10-floxed counterparts to account for
Cre-mediated toxicity.
See also Figure S3.
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of AF10 both at the genomic and protein levels after Cre-medi-
ated excision of Af10 (Figures S2F and S2G). Even though our
knockout strategy targeted the 30 exons of Af10 encoding the
octapeptide motif leucine zipper (OM-LZ) domains, we did
not observe a truncated AF10 protein with an anti-AF10 N
terminus antibody, suggesting that our model generates a
more extensive AF10 loss of function (Figure S2G). We did
not observe any changes in the DOT1L or AF17 protein levels
in AF10-deficient cells, suggesting that these complex mem-
bers are not adversely affected upon AF10 loss (Figure S2G).
Moreover, Af10 excision had no significant effect on the
colony-forming ability of HOXA9-MEIS1-transformed cells
(Figure S2H), and Af10-excised single cell clones could be
propagated indefinitely (data not shown). Interestingly, AF10
inactivation produced a dramatic decrease in H3K79me2 levels
in the HOXA9-MEIS1-transformed cells as well as in the AF10-
deficient fibroblasts, as assessed by western blotting, and this
loss of H3K79me2 could be rescued by ectopic AF10 expres-
sion (Figure 2B; Figure S2I). Notably, we observed that the
effect of Af10 deletion on H3K79me1 was less severe than
that of Dot1l deletion, which completely eliminated both
H3K79me1 and H3K79me2, consistent with DOT1L as the
sole H3K79 methyltransferase (Figure 2B). We next determined
H3K79 methylation levels in histones purified from Af10-deleted900 Cancer Cell 26, 896–908, December 8, 2014 ª2014 Elsevier Inc.HOXA9-MEIS1-transformed single-cell
clones using mass spectrometry (MS)
and used Dot1l wild-type or deleted
clones for comparison. Although Dot1l-
deleted clones harbored essentially un-
detectable levels of H3K79me1 and
H3K79me2, Af10-deleted cells had an
average of almost 20-fold reduction in
H3K79me2 levels and a much less severe
reduction in H3K79me1 levels, recapitu-
lating the results from western blotting
(Figure 2C; Figures S2J and S2K). These
results show that loss of AF10 impairsthe conversion of H3K79me1 to H3K79me2 in hematopoietic
cells.
Inactivation of AF10 Impairs the TransformingActivity of
MLL-AF9 and MLL-AF6
Leukemic transformation driven by different MLL fusion onco-
genes is dependent on DOT1L (Bernt et al., 2011; Chang et al.,
2010; Chen et al., 2013; Daigle et al., 2013; Deshpande et al.,
2013; Jo et al., 2011; Nguyen et al., 2011). We determined
whether the transforming activity of MLL-fusions was dependent
on AF10 because it is important for generation of H3K79me2.We
used MLL fusions with fusion partners that interact with DOT1L
(MLL-AF9 and MLL-AF10) or an MLL fusion that is believed to
operate through a distinct mechanism (MLL-AF6). We used
BM-derivedLSKs fromwild-typeorAf10fl/flmice toestablishblast
colony-forming cultures expressing MLL-AF9, MLL-AF6, or
MLL-AF10. We then deleted Af10 using a retrovirus expressing
the Cre recombinase and performed colony-forming cell assays
(Figure 3A). In the first week, Af10 deletion profoundly impaired
blast colony formation fromMLL-AF9-transformed LSKs, leading
to increasedmyeloid differentiation (Figures 3B–3D). Subsequent
replatings showed the emergence of blast colonies that had
escaped Af10 excision (data not shown). MLL-AF6-transformed
cells showed a similar dependence on AF10 (Figures 3B and
3E). In contrast, the blast colony-forming ability of LSKs
AC
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B Figure 4. Impact of AF10 Inactivation on
Leukemia Maintenance
(A) Survival curves for secondary leukemia from
MIT- or Cre-expressing primary MLL-AF9 leuke-
mias in the Af10fl/fl background compared with
MLL-AF9 leukemia cells from the Af10 wild-type
background (n = 6–10 mice for each cohort). n.s.,
not significant.
(B) Percent survival of mice injected with primary
MLL-AF6 leukemia cells in the Af10fl/fl background
after Cre or MIT expression (n = 6 for each cohort).
(C) Western blots showing H3K79me1 and
H3K79me2 in BM cells of three independent
Af10fl/fl or Af10/ MLL-AF9 leukemias. Total H3
was used as the loading control.
(D) Western blots showing H3K79me1 and
H3K79me2 in a representative Af10fl/fl or Af10/
MLL-AF9 leukemia treated with 10 mM of
EPZ004777 or the DMSO vehicle control.
(E) Representative experiment showing relative
proliferation as assessed by trypan blue exclusion
for Af10-floxed (MIT) or deleted (Cre) MLL-AF9
leukemia cells plotted as a percent of vehicle
control (DMSO) in various concentrations of
EPZ004777 at different time points (representative
of three independent experiments).
See also Figure S4.
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(Figure 3B; Figure S3). These results show that endogenous
AF10 is critical for MLL fusion-mediated transformation and that
this dependence can be rescued when the AF10OM-LZ domain
is present in the fusion protein, as in the case of MLL-AF10.
AF10 Loss of Function Impairs the Maintenance of
Diverse MLL-Driven Leukemias
Next we investigated the effects of Af10 deletion on leukemia
initiation from MLL-AF9-transformed cells. Af10 deletion signifi-
cantly delayed leukemia initiation by MLL-AF9 (Figure S4A). We
then deleted Af10 from established MLL-AF9- or MLL-AF6-
driven leukemias and injected cells into secondary recipient
mice to assess the impact on leukemia maintenance. AF10
inactivation significantly increased the latency of secondary
MLL-AF9 leukemias (Figure 4A) and completely abrogated
MLL-AF6 leukemia propagation (Figure 4B). Gene expression
analysis by quantitative PCR (qPCR) showed that expression
of key HOXA cluster genes (Hoxa5–10) and Meis1 was reduced
dramatically in AF10-deficient leukemias (Figure S4B). Next we
assessed global H3K79 methylation in Af10-deleted MLL-AF9
leukemia cells. Similar to the HOXA9-MEIS1-transformed cells,Cancer Cell 26, 896–908,we observed that AF10 inactivation dras-
tically reduced H3K79me2, whereas
H3K79me1 was affected to a lesser
degree (Figure 4C; Figure S4C). We
then investigated whether AF10-deficient
MLL-AF9 leukemias were still dependent
on DOT1L for their continued prolifera-
tion. We performed proliferation assays
on wild-type and AF10-deficient MLL-
AF9 leukemia cells using the DOT1L in-
hibitor EPZ004777 (Daigle et al., 2011).Treatment of the AF10-deficient MLL-AF9 leukemias with
EPZ004777 eliminated H3K79me2 and residual H3K79me1
and further reduced the expression of the Hoxa7–10 and Meis1
genes (Figure 4D; Figure S4D). Strikingly, AF10-deficient MLL-
AF9 leukemia cells showed an increased sensitivity to DOT1L in-
hibition compared with wild-type MLL-AF9 leukemia cells. AF10
deficiency substantially lowered both the time and dose required
to impair proliferation of MLL-AF9 leukemia cells (Figure 4E).
These results demonstrate that AF10may be a therapeutic target
inMLL-rearranged leukemias and that targeted disruption of the
DOT1L-AF10 interaction may also sensitize leukemias to small-
molecule DOT1L inhibition.
AF10 Inactivation Reverses MLL-AF9-Driven Gene
Expression and H3K79 Methylation Profiles
Next we performed a comprehensive investigation of histone
methylation and gene expression in the Af10-deleted leukemias
compared with the wild-type counterparts. We found dramatic
locus-specific changes in H3K79 methylation in the AF10-defi-
cient leukemias by ChIP-seq. The most remarkable change
was the marked decrease in H3K79me3 in the AF10-deficient
cells (Figures S5A and S5B). Specifically at the HOXA geneDecember 8, 2014 ª2014 Elsevier Inc. 901
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ation with the most profound reduction in H3K79me3, accom-
panied by a substantial decrease of H3K79me2 (Figure S5C).
H3K79me1, however, appeared to be either retained or
increased at theHoxa7–10 genes (Figure S5C). This discrepancy
between H3K79me1 and H3K79me2/3 prompted us to analyze
the genome-wide relationship between H3K79me1 and
H3K79me2 in greater detail. Our analysis showed that thousands
of genes, including most of the HOXA cluster genes, lost
H3K79me2 (Figure 5A, bottom quadrants), consistent with our
previous assessments of global H3K79me2 levels. Interestingly,
a few of these H3K79me2-depleted genes appeared to gain
H3K79me1 (Figure 5A, red box). We found that the genes with
H3K79me2 loss accompanied by an apparent H3K79me1 gain
were largely those with the highest absolute H3K79me2/3 levels
in MLL-AF9 leukemia (Figure 5A, colored from yellow to red) and
were highly enriched for MLL-AF9 target genes (Figure 5A,
circled dots). We confirmed the decrease in H3K79me2/3 and
retention of H3K79me1 at HOXA/MEIS1 promoters upon
Af10 excision more quantitatively by ChIP-qPCR, where the
input sample was used to assess relative enrichment (Fig-
ure S5D). We then conducted a meta-analysis of all 129 MLL-
AF9 target genes to assess changes in the relationships between
H3K79me1 and H3K79me2 upon Af10 deletion across the gene
body. Strikingly, we observed that Af10 deletion altered the rela-
tionship between H3K79me1 and H3K79me2 at the majority of
MLL-AF9 target genes, restoring it to a pattern resembling
non-MLL-AF9 target genes (Figures 5B and 5C, green dots
versus yellow dots). This reversal happened at all but a few
MLL-AF9 target genes, such as Eya1, Hectd1, and Baz1a (Fig-
ure S5E and data not shown). These results demonstrate that
AF10 loss of function prevented the conversion of H3K79me1
to H3K79me2/3 at most MLL-AF9 target genes, such as
Hoxa7, Hoxa9, Hoxa10, Meis1, Mef2c, and Runx2, resulting in
the depletion of H3K79me2/3 and the preservation or accumula-
tion of H3K79me1.
Given that Af10 excision erased H3K79me2, but not
H3K79me1, at critical target genes, we wanted to determine
how this influenced the expression of MLL fusion target genes.
Microarray analysis of AF10-deficient leukemias showed a sig-
nificant reduction in the expression of key transcripts associated
with MLL-rearranged leukemia (Table S3), and gene set enrich-
ment analysis (GSEA) showed that transcripts downregulated
upon Af10 deletion were significantly enriched for MLL-AF9
target genes (Figure 5D). Transcripts downregulated in AF10-
deficient leukemias were also significantly enriched for a previ-
ously reported gene set of DOT1L-regulated genes in MLL-AF9
leukemia (Figure S5F; Bernt et al., 2011). Therefore, the lack of
conversion of H3K79me1 to H3K79me2 corresponds with a
decrease in gene expression for most of the critical MLL-AF9
target genes. However, there are a few MLL-AF9 target genes,
such as Eya1, that show elevated H3K79me2 and increased
expression after AF10 inactivation, suggesting that these genes
may be regulated by alternative DOT1L complexes.
Af10 Deletion Impairs Dot1L Localization and Promotes
H3K27me3 at HOXA Genes
Next we assessed whether chromatin localization of MLL-AF9 or
of DOT1L was influenced in AF10-deficient cells. For this, we902 Cancer Cell 26, 896–908, December 8, 2014 ª2014 Elsevier Inc.made use of in vivo biotin tagging to tag either MLL-AF9
or DOT1L and performed ChIP using streptavidin-conjugated
beads followed by qPCR. Although there was no significant
difference in MLL-AF9 occupancy in Af10/ compared with
Af10fl/fl cells (Figure S5G), we observed significantly lower
DOT1L occupancy on the promoter-proximal regions of the
Hoxa7–10 genes in Af10/ cells (Figure 5E). In contrast to the
Hoxa7–10 genes, we observed significantly increased DOT1L
localization at the Eya1 promoter-associated region in Af10/
compared with Af10fl/fl leukemia cells (Figure S5H), which corre-
sponds with increased Eya1 promoter-associated H3K79me2/3
and mRNA expression upon Af10 deletion.
We next assessed whether there were changes in H3K27
methylation at MLL-AF9 target genes after Af10 deletion.
Because the Drosophila AF10 ortholog plays a role in Polycomb
repulsion from homeotic loci, we wanted to determine whether
AF10 played a similar role in the spread of repressive PRC2
activity on HOX genes in MLL-AF9 leukemia. Our ChIP-qPCR
analysis of H3K27me3 showed a significant increase in
H3K27me3 at the promoters of Hoxa7–10 genes in Af10/
leukemias (Figure S5I). We then performed ChIP-seq for
H3K27me3 to assess whether H3K79 diminution was generally
accompanied by an H3K27 increase in other loci. Our analysis
showed alterations of H3K27 on various genes in the Af10-
deleted leukemias, but, strikingly, genes that lost H3K79me3
or H3K79me2 and concomitantly gained high levels of
H3K27me3 were almost exclusively comprised of exactly those
HOXA cluster genes that are highly expressed in LSKs and
are associated with stem cell self-renewal (Krivtsov et al.,
2006; Figures S5J and S5K). These results demonstrate that
AF10 has specific chromatin modulatory activity at the self-
renewal-associated HOXA cluster genes in MLL-AF9 leukemia
cells. Importantly, similar to our observation in normal GMPs,
the continued presence of H3K79me1 was insufficient to
prevent the increase in H3K27me3 at the Hoxa7–10 gene pro-
moters in the Af10-deleted leukemias, thereby disrupting the
mutually exclusive nature of H3K79 and H3K27 methylation
normally observed across the genome (Figure S5L; Bernt
et al., 2011). These results show that inactivation of AF10
leads to impaired DOT1L association with HOXA cluster
genes, loss of higher H3K79 methylated states, and the spread
of H3K27me3, which coincides with a decrease in gene
expression.
AF10 Enhances the Enzymatic Activity of DOT1L
Next we tested whether AF10 can directly affect the histone
methyl-transferase (HMTase) activity of DOT1L in cell-free
HMTase assays using purified FLAG-tagged human DOT1L,
alone or in a complex with full length human AF10, and reconsti-
tuted unmodified mononucleosomes and radioactive 3H-S-ad-
enosyl-methionine substrates (Figures 6A and 6B). We found
that the DOT1L-AF10 complex had greater HMTase activity
than DOT1L alone, as assessed by 3H incorporation into his-
tones in filter binding assays (Figure 6C). Next we extracted
histones from the DOT1L- or DOT1L-AF10-methylated mono-
nucleosomes and investigated H3K79me0, H3K79me1, and
H3K79me2 using MS, which confirmed that the DOT1L-AF10
complex had a significantly higher overall methylating activity
compared with DOT1L alone (Figure 6D; Figure S6A–S6C). In
Figure 5. Genomic and Epigenomic Changes upon Af10 Deletion
(A) Scatter plot showing genome-wide changes in the values of promoter-proximal H3K79me1 (x axis) or H3K79me2 (y axis) in Af10fl/fl versus Af10/ leukemias.
Each dot represents the difference in averaged methylation values around the promoter-proximal regions (2 kb to +2 kb around the TSS). Positive and negative
values reflect increases and decreases, respectively, in Af10/ compared with Af10fl/fl leukemias. Methylation values are colored according to absolute
H3K79me2 values in wild-type MLL-AF9 leukemia (blue, least methylation; red, highest methylation).
(B) Representativemeta-analysis plot showing an averaged profile across the gene body from the TSS to the transcription end site (TES) of MLL-AF9 target genes
compared with control genes. Profiles of Af10fl/flMLL-AF9 leukemias (blue) compared with their Af10/ counterparts (red) are presented. Light colors represent
H3K79me1, and dark colors represent H3K79me2. MLL-AF9 targets are genes bound by MLL-AF9, and non-MLL-AF9 target genes are a size- and expression-
matched set of genes that are not bound by MLL-AF9.
(C) Scatter plot showing the genome-wide relative relationship between H3K79me1 and H3K79me2 values around promoter-proximal regions. Values are
representative of five independent replicates for each group.
(D) Enrichment of MLL-AF9 target genes in Af10/ compared with Af10fl/fl leukemias as shown by GSEA. The top 20MLL-AF9 targets downregulated in Af10/
leukemia are shown on the right. FDR, false discovery rate.
(E) ChIP for DOT1L protein at the promoter-proximal regions of the indicated genes in MLL-AF9 leukemias. n = 2, *p < 0.05.
Error bars represent SD. See also Figure S5 and Table S3.
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Figure 6. Effect of AF10 on the HMTase
Activity of DOT1L
(A) Schematic depiction of the experimental
design. SAM, S-adenosylmethionine,; SAH, S-ad-
enosylhomocysteine.
(B) FLAG-tagged DOT1L overexpressed either
alone or in combination with untagged AF10 in
insect cells and purified using FLAG affinity purifi-
cation is shown by Coomassie staining.
(C) Bar graph showing quantification of methyl-
ation as performed by filter binding followed by
liquid scintillation counting at various time points
denoted on the x axis. cpm, counts per million.
n = 3, *p < 0.01 in each case.
(D) Comparative levels of H3K79me0, H3K79me1,
and H3K79me2 by MS in nucleosomes incubated
with a human DOT1L fragment expressed in E. coli
(positive control), full-length human DOT1L, or
DOT1L+AF10 (n = 2, *p < 0.05). Ion intensities of
methylated peptides (residues 74–84) are scaled
relative to an internal standard.
(E) Ratio of H3K79me2/me1 normalized to an in-
ternal standard under the different conditions. *p <
0.05.
Error bars represent SD. See also Figure S6.
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had a significantly higher H3K79me2/me1 ratio than those meth-
ylated by DOT1L alone (Figure 6E). These results demonstrate
that AF10 plays a crucial role in enhancing the HMTase activity
of DOT1L, influencing its ability to stimulate higher order
H3K79 methylation.
AF10 Controls HOXA Gene Expression and Proliferation
of NUP98-NSD1-Transformed Cells
Our observations from LSKs, GMPs, and different MLL
fusion leukemias suggest that higher-degree H3K79 methyl-
ation mediated by the DOT1L-AF10 complex is critical for
HOX gene expression irrespective of the cellular context.
D. melanogaster studies have shown that both DOT1L and
AF10 orthologs are required for normal HOX gene expression
(Perrin et al., 2003; Shanower et al., 2005), suggesting an
evolutionarily conserved function of the DOT1L-AF10 complex
in homeotic gene expression. Because aberrant HOX gene
expression is not limited to MLL-rearranged leukemia, we904 Cancer Cell 26, 896–908, December 8, 2014 ª2014 Elsevier Inc.wondered whether the DOT1L-AF10
complex might also regulate HOX gene
expression and, consequently, trans-
forming activity of other AML-inducing
oncogenes that show aberrant HOX
gene activation. The NUP98-NSD1
fusion resulting from a chromosomal
translocation is observed in 16% of
cytogenetically normal pediatric AML
patients and in a small subset of adult
AML patients (Fasan et al., 2013; Hollink
et al., 2011; Thol et al., 2013). NUP98-
NSD1-positive AML patients possess
high-level HOXA gene expression and
have a very poor prognosis (Hollinket al., 2011). We generated a retrovirus that expresses
NUP98-NSD1 and transduced LSK cells from either wild-
type or homozygous Af10-floxed mice. NUP98-NSD1-trans-
duced cells proliferated indefinitely in culture and displayed
features of differentiation arrest, as assessed by immunophe-
notype and morphology (Figures S7A and S7B). Biallelic
Af10 deletion led to a dramatic decrease in H3K79 dimethyla-
tion, accompanied by a more subtle decrease in H3K79
monomethylation in the NUP98-NSD1-transformed cells (Fig-
ure S7C). Furthermore, AF10 inactivation led to a significantly
reduced expression of the Hoxa7–10 cluster (Figure S7D).
Importantly, deletion of either Af10 or Dot1l in NUP98-NSD1
transformed bone marrow cells dramatically impaired their
proliferation and increased apoptosis (Figures 7A and 7B; Fig-
ure S7E), and cells growing after 14 days had incomplete
deletion of Dot1l or Af10 (data not shown). NUP98-NSD1
cells deleted of either Af10 or Dot1l demonstrated a cellular
morphology consistent with differentiation (Figure 7C and
data not shown). These findings suggest that, similar to
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Figure 7. Role of the DOT1L-AF10 Complex
Beyond MLL-Rearranged Leukemia
(A) Representative picture of a well with MIT- or
Cre-expressing NUP98-NSD1-transformed cells in
the Dot1lWT/WT and Dot1lfl/fl backgrounds at day 14
after culture.
(B) Relative proliferation of NUP98-NSD1 cells after
Af10 or Dot1l deletion (Cre) compared to wild-type
controls presented as a percentage of their Af10 or
Dot1l non-deleted (MIT) counterparts. n = 3, *p <
0.05. Error bars represent SD.
(C) Wright-Giemsa-stained cytospins of NUP98-
NSD1-transformed cells 7 days after MIT or Cre
expression in the Af10WT/WT or Af10fl/fl back-
grounds.
See also Figure S7.
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by NUP98-NSD1 is critically dependent on H3K79 methylation
mediated by the DOT1L-AF10 complex.
NUP98-NSD1-Transformed Cells Are Sensitive to Small-
Molecule DOT1L Inhibition
The observations above using Dot1l or Af10 conditional
knockout mice indicated that cells transformed with HOX-acti-
vating oncogenes other than MLL fusion proteins might show
sensitivity to therapeutic targeting of DOT1L activity. Given the
clear clinical implication of this hypothesis, we tested the sensi-
tivity of NUP98-NSD1-transformed cells to pharmacological
DOT1L inhibition. Treatment of the NUP98-NSD1-transformed
cells with the DOT1L inhibitor EPZ004777 significantly reduced
global and promoter-associated H3K79me2 as well as Hoxa7–
10 gene expression (Figures 8A and 8B; Figure S8A). Notably,
the effect of EPZ00477 exposure on HOXA gene expression
led to a dramatic dose-dependent decrease in proliferation start-
ing from day 7 after exposure to the inhibitor (Figure 8C) and
accompanied by increased differentiation and apoptosis (Fig-
ure 8D; Figure S8B). The sensitivity of NUP98-NSD1 cells to
EPZ004777 could be completely rescued by retroviral overex-
pression of HOXA9-MEIS1 (Figure S8C), demonstrating that
NUP98-NSD1-mediated transformation was critically depen-
dent on DOT1L-mediated regulation of HOXA/MEIS1 gene
expression. These results provide compelling evidence in sup-
port of a broader role for H3K79 methylation, mediated by the
DOT1L-AF10 complex, in leukemogenic HOXA gene regulation
and oncogenesis. These data also indicate that therapeutic
targeting of the DOT1L activity may provide benefits in multiple
leukemia subtypes showing aberrant HOXA gene activation.Cancer Cell 26, 896–908,DISCUSSION
The biological responses associated with
histone methylation are determined both
by the amino acid residue and the degree
of methylation (Kouzarides, 2007). H3K79
methylation is associated with actively
transcribed genes and euchromatin in
multiple species. Mono-, di-, and trime-
thylation of H3K79 are all solely catalyzed
by DOT1L inmultiple organisms (reviewedin Nguyen and Zhang, 2011). In S. cerevisiae, mutation of H3K79
influences SIR2 binding and heterochromatin formation, there-
fore affecting gene activity. Whether H3K79 methylation influ-
ences similar mechanisms to control gene expression in
mammalian cells is unclear. Our results suggest that different
levels of H3K79 methylation serve as a ‘‘volume control’’ mech-
anism for gene expression during hematopoiesis and leukemia
development, with higher degrees of H3K79 methylation corre-
lating with elevated levels of gene expression. Of particular inter-
est, genes decorated with H3K79me1 but not H3K79me2/3 are
unable to maintain high-level expression either in developing he-
matopoietic cells or leukemia cells. Of note, H3K27me3 invaded
HOX loci even though H3K79me1 was present. Therefore, the
loss of one methyl group on H3K79 appears to have allowed
gene repression and H3K27me3 accumulation. This suggests
that, during hematopoietic development, the H3K79 methylation
state decreases as myeloid development progresses, therefore
ensuring a finely tuned decrease in gene expression to the point
at which repressive mechanisms dominate. Such processes
therefore allow developing myeloid cells the potential to rapidly
and faithfully modulate expression of genes that are highly ex-
pressed in less differentiated cells until cells are fully committed
to a particular fate. However, this mechanism presents a risk of
being co-opted by leukemogenic oncoproteins, a mechanism
that is taken advantage of by MLL or NUP98-fusions.
There is growing appreciation of aberrant chromatin modifica-
tions in cancer cells. One fascinating aspect is the apparent
oncogenic impact of abnormal variations in the degree of histone
methylation at particular histone residues. In MLL-AF9 leukemia
cells, we find a decrease in H3K79me1 and a concomitant
increase in H3K79me2/3 at MLL-AF9 target genes, whichDecember 8, 2014 ª2014 Elsevier Inc. 905
AC D
B Figure 8. Effect of Pharmacological DOT1L
Inhibition on NUP98-NSD1-Transformed
Cells
(A) The H3K79me2 level at the promoters of the
Hoxa7–10 andMeis1 genes upon DOT1L inhibition
with 10 mM EPZ004777 for 7 days was assessed
by ChIP with an H3K79me2-specific antibody fol-
lowed by qPCR. *p < 0.05.
(B) Expression of HOXA/MEIS1 genes 7 days after
treatment of NUP98-NSD1-transformed BM cells
with 10 mM EPZ004777 relative to DMSO vehicle
carrier-treated cells. *p < 0.05.
(C) Relative proliferation of NUP98-NSD1-trans-
formed cells during 17 days of incubation with
varying concentrations of EPZ004777 plotted as a
percentage of the vehicle control-treated cells.
(D) Wright-Giemsa-stained cytospins of NUP98-
NSD1-transformed cells 10 days after treatment
with DMSO or the EPZ004777 inhibitor.
Error bars represent SD. See also Figure S8.
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higher-methylated states. The MLL-AF9 fusion protein prevents
a differentiation-associated decrease in higher-degree H3K79
methylation at key MLL-AF9 target genes, including the HOXA
genes, leading to the perpetuation of a constantly self-renewing
state. These findings underscore the critical roles specific
methylation states play in oncogenesis. Other examples of
specific degrees of histone methylation contributing to onco-
genic development are the recently described gain-of-function
mutations in the H3K27 methyltransferase EZH2, leading to hy-
perdimethylation and hypertrimethylation of H3K27 in B cell lym-
phoma (McCabe et al., 2012a; Sneeringer et al., 2010) as well as
the accumulation of H3K36me2 in subsets of multiple myeloma
and acute lymphoid leukemia cells harboring chromosomal
translocations or activating mutations of the H3K36methyltrans-
ferase MMSET/NSD2 (Martinez-Garcia et al., 2011).
The low H3K79me1/high H3K79me2 pattern we observed on
MLL-AF9 target genes could reflect enhanced DOT1L recruit-
ment and/or enzymatic activity at these genes. A recent study
demonstrated that inactivation of the C. elegans AF10 homolog
abrogates chromatin localization of the C. elegans homolog of
DOT1L (Cecere et al., 2013). In our study, we demonstrate
that AF10 depletion reduces DOT1L localization to HOX genes,
indicating that AF10 plays a role in locus-specific DOT1L recruit-
ment. Our observation that some genes, including some MLL-
AF9 target genes such as Eya1, Hectd1, and Baz1a, gain
H3K79 methylation upon Af10 deletion suggests that AF10 is
responsible for DOT1L localization on most, but not all, MLL-
AF9 target genes and that, in the absence of AF10, DOT1L levels
and, consequently, H3K79 methylation may be relocated to
other chromatin loci, potentially through other DOT1L cofactors.906 Cancer Cell 26, 896–908, December 8, 2014 ª2014 Elsevier Inc.Although AF10 inactivation dramatically
impairs leukemia initiation and mainte-
nance, AF10 deficiency does not
completely preclude MLL-AF9 leukemic
outgrowth. In the case of MLL-AF6,
however, AF10 depletion seems to
completely inhibit leukemia development.
The difference in the degree of AF10dependence between these two leukemias may be attributable
to the ability of MLL-AF9, but not MLL-AF6, to recruit DOT1L
to HOX and other loci. It is important to mention that both leuke-
mias show absolute dependence on H3K79 methylation
because DOT1L inhibition in AF10-deficient MLL-AF9 leukemias
swiftly and completely eliminates those cells.
We demonstrate that AF10 augments the HMTase activity of
DOT1L. AF10 is therefore important for both the recruitment
and enzymatic activity of DOT1L, analogous to cofactors of other
chromatin-modifying complexes (Dou et al., 2006; Wysocka
et al., 2005). There is increasing interest in the development of
small-molecule inhibitors against chromatin modulators. Studies
have shown that inhibition of chromatin-modifying enzymes can
have therapeutic benefits in preclinical models (Chen et al., 2013;
Daigle et al., 2011; Deshpande et al., 2013; McCabe et al.,
2012b). A small-molecule DOT1L inhibitor is currently in phase
I clinical trials for the therapy ofMLL-rearranged leukemia (Daigle
et al., 2013). It is worth noting that most drug-screening efforts
aimed at therapeutically targeting the HMTase activity of
DOT1L use the catalytically active DOT1L N-terminal 1–416
amino acid fragment. In our study, we demonstrated that full-
length DOT1L in complex with AF10 not only has a significantly
enhanced HMTase activity but is also better able to produce
H3K79 dimethylation than DOT1L alone. Our data not only pro-
vide an important starting point for further detailed analyses of
the enzymology of H3K79 methylation but also indicate that
the DOT1L-AF10 complex might be a more physiologically rele-
vant target for future drug development efforts.
Efforts to target chromatin-modifying proteins are increasingly
gaining traction. One prime example of this is small molecule
inhibition of the PRC2 complex in lymphoma cells, for which
Cancer Cell
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2012b; Qi et al., 2012). These rapid advances predict an
emerging wave of anticancer therapeutics based on the inhibi-
tion of chromatin regulatory factors. Our results demonstrate
that, in addition to histone methyltransferases themselves,
the identification of oncogenic dependencies on chromatin co-
factors may present additional avenues for therapeutic interven-
tion in malignancies with aberrant changes in the epigenome.
Targeting the DOT1L-AF10 interaction may synergize with and,
therefore, improve the efficacy of agents that inhibit DOT1L.
These studies present a rationale for therapeutic targeting of
the DOT1L-AF10 interaction and suggest that dimethylation
and trimethylation of H3K79 via theDOT1L complex is a potential
therapeutic target in an array of different leukemias and,
perhaps, other tumor types associated with elevated HOX
gene expression.
EXPERIMENTAL PROCEDURES
ChIP-qPCR and ChIP-Seq
ChIPwas performed as described previously (Bernt et al., 2011). Briefly, cross-
linking was performedwith 1% formalin, and the cells were lysed in SDS buffer.
Sonication was used to fragment DNA. ChIP for H3K79me1, H3K79me2,
H3K79me3, and H3K27me3 was performed using the antibodies ab2886,
ab3534, and ab2621 (Abcam) and 07-449 (Millipore) specific to the respective
modifications. Eluted DNA fragments were analyzed by qPCR or subjected to
sequencing using next-generation Ilumina sequencing. More details can be
obtained in the Supplemental Experimental Procedures.
Mice
A pFlexible-based targeting vector containing an 2.7 kb genomic locus re-
gion that included exons 17 and 18 of Af10 (reference transcript REFSEQ
NM_010804) flanked by loxp sites was used to target CJ9 ES cells (129 back-
ground). Conditional mice were maintained on a B6/129 background (Ta-
conic). The generation of Dot1l knockout mice has been described previously
(Bernt et al., 2011). Dot1lfl/flmice were crossed to Mx1-Cre mice (The Jackson
Laboratories), and theMx1-Cre allele was maintained as a heterozygous allele
on a mixed B6/129 background. Genotyping strategies, primers, and condi-
tions are described in the Supplemental Experimental Procedures. All animal
experiments described in this study, including the experiments with condi-
tional knockout mice as well as mouse BM transplantation models, were
approved by and adhered to the guidelines of the Memorial Sloan-Kettering
Cancer Center and the Children’s Hospital Boston Institutional Animal Care
and Use Committees.
Small-Molecule Inhibitor
EPZ004777 was synthesized by the laboratory of Jay Bradner (Dana Farber
Cancer Institute). 50 mM stock solutions were prepared in DMSO and stored
at20C. Serial dilutions of stock solutions were carried out just prior to use in
each experiment, and final DMSO concentrations were kept at or below
0.02%.
Data Analysis and Statistical Methods
The significance for all individual experiments described in themanuscript was
calculated using a two-tailed unpaired Student’s t test in Microsoft Excel or
GraphPad Prism. For mouse survival curves, a log rank test was used to calcu-
late statistical significance using GraphPad Prism. Raw expression data were
normalized using Genepattern software by a robust multiarray average algo-
rithm with quantile normalization and background correction. Probe sets that
had 50%ormore present calls (using theMAS5 algorithm) were marked as ex-
pressed and the remainder as not expressed. The expressed probe sets were
further divided into three groups of high,medium, and low expression based on
raw expression values. Gene set enrichment analysis of the microarray was
performed with GSEA, and relative changes in methylation values were plotted
using Icanplot software (http://www.icanplot.org) (Sinha andArmstrong, 2010).CaACCESSION NUMBERS
ChIP and microarray data were deposited at the NCBI Gene Expression
Omnibus under accession number GSE54500.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
eight figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.ccell.2014.10.009.
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